Simpson Thacher represented the underwriters in a U.S. registered public offering of $5 billion of senior notes with maturities ranging between three and ten years by AstraZeneca Finance LLC, a wholly-owned subsidiary of AstraZeneca PLC. The offering closed on February 26, 2024, with the net proceeds to be used for general corporate purposes, which may include the refinancing of existing indebtedness.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
The Simpson Thacher team included Mark Brod, Joann Kim and Rob Bloomer (Capital Markets); Jonathan Cantor (Tax); Vanessa Burrows and Nawa Lodin (Healthcare Regulatory); Bobbie Burrows and Alysha Sekhon (IP); and Jennie Getsin (FINRA and Blue Sky).